XML 38 R23.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Organization and Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Jun. 30, 2024
Accounting Policies [Abstract] |
Schedule of Company's Current Pipeline | The following table presents the Company’s current pipeline:
Therapeutic Area | Name | Stage | Product Rights
Cardiometabolic | plozasiran (ARO-APOC3) | Phase 3 | Arrowhead
| zodasiran (ARO-ANG3) | Phase 2b | Arrowhead
| olpasiran | Phase 3 | Amgen
Pulmonary | ARO-RAGE | Phase 1/2a | Arrowhead
| ARO-MUC5AC | Phase 1/2a | Arrowhead
| ARO-MMP7 | Phase 1/2a | Arrowhead
Liver | GSK-4532990 | Phase 2b | GSK
| fazirsiran | Phase 3 | Takeda and Arrowhead
| daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989) | Phase 2 | GSK
| ARO-PNPLA3 | Phase 1 | Arrowhead
| ARO-C3 | Phase 1/2a | Arrowhead
| ARO-CFB | Phase 1/2a | Arrowhead
Muscle | ARO-DUX4 | Phase 1/2a | Arrowhead
| ARO-DM1 | Phase 1/2a | Arrowhead
Central Nervous System (CNS) | Various | Pre-Clinical | Arrowhead

X
- Definition Schedule of Current Products + References No definition available. + Details
Name: | arwr_ScheduleOfCurrentProductsTableTextBlock
Namespace Prefix: | arwr_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration